Acne Exacerbation After Tofacitinib Treatment for Alopecia Areata

This source reports that JAK inhibitors, such as ruxolitinib, baricitinib, and tofacitinib, have led to hair regrowth in alopecia areata patients and animal models, but their long-term safety and effectiveness remain uncertain, with ongoing trials to further investigate these factors.

This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.

This systematic review found that Janus kinase inhibitors have shown beneficial effects for psoriasis and alopecia areata, with promising preliminary results in other skin conditions, though more research is needed to define dosing and safety profiles.

This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.

This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.